Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
PF-04691502 is an inhibitor of PI3K and mTOR kinase. Published data support the hypothesis
that a PI3K/mTOR antagonist in combination with letrozole might mitigate the intrinsic or
acquired resistance to hormonal therapy and restore hormone sensitivity in high risk (high
Ki-67) patient population of hormone-sensitive breast cancers. In addition, Ki-67, a marker
of cellular proliferation, could be used to select those patients who benefit from treatment
with a PI3K-pathway inhibitor.